baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Novo Nordisk A/S/ DK0062498333 /

- -	Chg. -	Volume	Bid9:04:24 AM	Ask9:04:24 AM	Market Capitalization	Dividend Y.	P/E Ratio
76.88EUR	-	- Turnover: -	-Bid Size: -	-Ask Size: -	415.87 bill.EUR	-	-

GlobeNewswire 05-15 Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...

GlobeNewswire 05-15 Aeterna Zentaris Reports First Quarter 2024 Financial Results

GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 05-07 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference

TeleTrader 04-25 Europe opens mostly down after corporate earnings

GlobeNewswire 04-22 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...

GlobeNewswire 04-22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...

GlobeNewswire 04-11 Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

GlobeNewswire 04-02 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...

GlobeNewswire 04-02 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

GlobeNewswire 03-28 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...

GlobeNewswire 03-27 Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...

GlobeNewswire 03-25 Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...

GlobeNewswire 03-18 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...

GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...

GlobeNewswire 03-15 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...

GlobeNewswire 03-12 Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...

GlobeNewswire 03-12 ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOA...

GlobeNewswire 03-11 FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer

GlobeNewswire 03-07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...

GlobeNewswire 03-07 Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...

GlobeNewswire 03-01 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...

GlobeNewswire 02-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...

Novo Nordisk A/S/ DK0062498333 /

If you wish to receive reply to your feedback, please provide your email address.